Optimization of NIBS for Treatment of Addiction
for Opioid-use Disorder
Sites in Hinsdale +2 more locations
Sponsor: Case Western Reserve University
Sex: All·Age: 18 - 85
Code: NCT04379115·Recruiting·Listed May 2020
Paid Clinical Trials in Hinsdale, IL
As of August 2026, 52 paid clinical trials are recruiting in Hinsdale, Illinois. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Filter results
52 clinical trials
Get a weekly email when new trials open in Hinsdale, IL.
Nasal Antisepsis for C. Auris Prevention
for Candida Auris Infection
Sites in Hinsdale & Chicago
Sponsor: Mary K Hayden
Sex: All·Age: 18+
Code: NCT06282510·Phase 4·Recruiting·Listed Feb 2024
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
for Multi-Drug Resistant Organism Colonization
Sites in Hinsdale +3 more locations
Sponsor: Emory University
Sex: All·Age: 18+
Code: NCT06321536·Phase 2·Recruiting·Listed Mar 2024
Outpatient Visits Versus Telehealth for Postoperative Care After Minimally Invasive Gynecologic Surgery
for to Determine Whether Patient Satisfaction With Postoperative Telehealth Follow-up is Non-inferior to In-person Clinic Visits
Sites in Hinsdale & Chicago
Sponsor: University of Chicago
Sex: Female·Age: 18+
Code: NCT07420114·Recruiting·Listed Feb 2026
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for Non-squamous Non-small Cell Lung Cancer
Drug: Rilvegostomig
Sites in Hinsdale, Chicago +59 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06627647·Phase 3·Recruiting·Listed Oct 2024
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
for Non-small Cell Lung Cancer
Drug: Rilvegostomig
Sites in Hinsdale, Chicago +63 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06692738·Phase 3·Recruiting·Listed Nov 2024
Observational Study Protocol: LIVER-R
for Hepatobiliary Cancers
Sites in Hinsdale, Evergreen Park +22 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT06252753·Recruiting·Listed Feb 2024
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
for Non-Small Cell Lung Cancer
Drug: Rilvegostomig
Sites in Hinsdale +48 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06357533·Phase 3·Recruiting·Listed Apr 2024
Study of BHV-1400 in IgA Nephropathy
for IgA Nephropathy
Drug: BHV-1400
Sites in Hinsdale +13 more locations
Sponsor: Biohaven Therapeutics Ltd.
Sex: All·Age: 18 - 65
Code: NCT07054684·Phase 1·Recruiting·Listed Jul 2025
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
for APOL1-Mediated Kidney Disease
Sites in Hinsdale, Chicago +76 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18 - 65
Code: NCT06824987·Phase 2·Recruiting·Listed Feb 2025
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
for HER2-positive Gastric Cancer
Drug: Rilvegostomig
Sites in Hinsdale, Chicago +43 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06764875·Phase 3·Recruiting·Listed Jan 2025
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
for Non-small Cell Lung Cancer
Drug: Osimertinib
Sites in Hinsdale, North Chicago +26 more locations
Sponsor: AstraZeneca
Sex: All·Age: 18+
Code: NCT06350097·Phase 3·Recruiting·Listed Apr 2024